Microlin Bio Announces Issuance Of Thirty Seven Additional Patents For The Use Of Microrna In Cancer Treatment And Diagnosis

NEW YORK--(BUSINESS WIRE)--Microlin Bio, Inc., a therapeutics company focusing on microRNA and their role in cancer, today announced that it has received issuance of thirty seven (37) new patents related to the use of microRNA in cancer treatment and diagnosis. The newly issued patents expand the company’s already large intellectual property estate, which includes over 138 pending and 132 issued patents, and extends important intellectual property for the use of microRNA in the treatment and diagnosis of cancer.

“Collectively, they further expand Microlin's intellectual property estate surrounding the use of microRNAs in cancer therapy and diagnosis.”

"These newly issued patents contain broad claims which provide important long-term exclusivity for the use of microRNA in cancer," said Joseph Hernandez, CEO and Chairman of Microlin Bio. "Collectively, they further expand Microlin's intellectual property estate surrounding the use of microRNAs in cancer therapy and diagnosis."

About Microlin Bio, Inc.

Microlin Bio is a development stage biotechnology company focused primarily on the development of microRNA based therapeutics and diagnostics to treat cancer from technologies licensed from the Ohio State University.